The role of phenoconversion in the pharmacogenetics of psychiatric medication

References

• 1. Indiana University. The Flockhart Cytochrome P450 Drug–Drug Interaction Table (2021). https://drug-interactions.medicine.iu.edu/ (Accessed 31 March 2023).
  Google Scholar
• 2. Kirchheiner J, Nickchen K, Bauer M et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry 9(5), 442–473 (2004).
  Medline CASGoogle Scholar
• 3. Lima JJ, Thomas CD, Barbarino J et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C19 and proton pump inhibitor dosing. Clin. Pharmacol. Ther. 109, 1417–1423 (2021).
  MedlineGoogle Scholar
• 4. Bousman CA, Stevenson JM, Ramsey LB et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants. Clin. Pharmacol. Ther. doi: 10.1002/cpt.2903 (2023) (Online).
  Google Scholar
• 5. Brouwer J, Nijenhuis M, Soree B et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction between CYP2C19 and CYP2D6 and SSRIs. Eur. J. Hum. Genet. doi: 10.1038/s41431-021-01004-7 (2021) (Online).
  MedlineGoogle Scholar
• 6. Hahn M, Müller DJ, Roll SC. Frequencies of genetic polymorphisms of clinically relevant gene–drug pairs in a german psychiatric inpatient population. Pharmacopsychiatry 53, 1–9 (2020).
  Google Scholar
• 7. Mostafa S, Kirkpatrick CMJ, Byron K et al. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes. J. Neural Transm. 126, 5–18 (2019).
  Medline CASGoogle Scholar
• 8. Scherf-Clavel M, Frantz A, Eckert A et al. Effect of CYP2D6 pharmacogenetic phenotype and phenoconversion on serum concentrations of antidepressants and antipsychotics: a retrospective cohort study. Int. J. Clin. Pharm. doi: 10.1007/s11096-023-01588-8 (2023) (Epub ahead of print).
  MedlineGoogle Scholar
• 9. Cicali EJ, Elchynski AL, Cook KJ et al. How to integrate CYP2D6 phenoconversion into clinical pharmacogenetics: a tutorial. Clin. Pharmacol. Ther. 110, 677–687 (2021).
  MedlineGoogle Scholar
• 10. Bousman CA, Wu P, Aitchison KJ et al. Sequence2Script: a web-based tool for translation of pharmacogenetic data into evidence-based prescribing recommendations. Front. Pharmacol. 12 doi:10.3389/fphar.2021.636650 (2021) (Online).
  MedlineGoogle Scholar
• 11. Hahn M, Roll SC. Pharmakogenetik zur Erhöhung der Arzneimitteltherapiesicherheit. Psychopharmakotherapie 29, 17–26 (2022).
  Google Scholar
• 12. Kiss ÁF, Vaskó D, Déri MT et al. Combination of CYP2C19 genotype with non-genetic factors evoking phenoconversion improves phenotype prediction. Pharmacol. Rep. 70, 525–532 (2018).
  Medline CASGoogle Scholar
• 13. Hagg S, Spigset O, Dahlqvist R. Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br. J. Clin. Pharmacol. 51, 169–173 (2001).
  Medline CASGoogle Scholar
• 14. Klieber M, Oberacher H, Hofstaetter S et al. CYP2C19 phenoconversion by routinely prescribed proton pump inhibitors omeprazole and esomeprazole: clinical implications for personalized medicine. J. Pharmacol. Exp. Ther. 354, 426–430 (2015).
  Medline CASGoogle Scholar
• 15. Hole K, Arnestad M, Molden E et al. Dose-dependent inhibition of CYP2D6 by bupropion in patients with depression. J. Clin. Psychopharmacol. 41(3), 281–285 doi: 10.1097/JCP.0000000000001387 (2021) (Online).
  Medline CASGoogle Scholar
• 16. Hoffmann M, Russmann S, Niedrig DF. Severe CNS depression with duloxetine, ciprofloxacin and CYP2D6 deficiency-role and recognition of drug–drug–gene interactions. Eur. J. Clin. Pharmacol. 78(4), 703–705 (2022).
  Medline CASGoogle Scholar
• 17. Hicks JK, Sangkuhl K, Swen JJ et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin. Pharmacol. Ther. 102, 37–44 (2017).
  Medline CASGoogle Scholar
• 18. Roll SC, Hahn M. Rates of divergent pharmacogenes in a psychiatric cohort of inpatients with depression – arguments for preemptive testing. J. Xenobiot. 12(4), 317–328 (2022).
  Medline CASGoogle Scholar
• 19. Hahn M, Roll SC. The influence of pharmacogenetics on the clinical relevance of pharmacokinetic drug–drug interactions: drug–gene, drug–gene–gene and drug–drug–gene interactions. Pharmaceuticals (Basel) 14(5), 487 (2021).
  Medline CASGoogle Scholar
• 20. Hahn M, Roll SC. A collaborative approach in pharmacogenetic testing: actionable genotypes of antidepressants and their avoidance in a retrospective study. J. Explor. Res. Pharmacol. doi: 10.14218/JERP.2022.00054;S (2022) (Online).
  MedlineGoogle Scholar
• 21. Stäuble CK, Jeiziner C, Bollinger A et al. A guide to a pharmacist-led pharmacogenetic testing and counselling service in an interprofessional healthcare setting. Pharmacy 10(4), 86 (2022).
  MedlineGoogle Scholar
• 22. Weitzel KW, Duong BQ, Arwood MJ et al. A stepwise approach to implementing pharmacogenetic testing in the primary care setting. Pharmacogenomics 20(15), 1103–1112 (2019).
  CASGoogle Scholar
• 23. Hahn M, Eckert A, Frantz A et al. Barriers for implementation of PGx testing in psychiatric hospitals in Germany-results of the FACT-PGx study. Fortschr. Neurol. Psychiatr. doi:10.1055/a-2060-0694 (2023) (Online).
  MedlineGoogle Scholar
• 24. Morris SA, Alsaidi AT, Verbyla A et al. Cost effectiveness of pharmacogenetic testing for drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines: a systematic review. Clin. Pharmacol. Ther. 112(6), 1318–1328 (2022).
  Medline CASGoogle Scholar